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Alzheimer’s disease (AD) is a global pub-
lic health threat with the prevalence pro-
jected to triple over the next 50 years.
While substantial progress has been made
in understanding the pathological time-
line and developing biomarkers, one area
remains relatively neglected: the dispropor-
tionate burden that women face. Women
not only make up the majority of care-
givers but also make up over two-thirds of
Alzheimer’s patients (1, 2).
Currently, of the several thousand
research studies published in the field of
AD, only a tiny fraction are devoted specif-
ically to sex differences. The higher preva-
lence of AD in women has traditionally
been assumed to be due to longer female
life expectancy. Differences in educational
level, cognitive detection-biases, sex hor-
mones, and genetics have been proposed as
other possible causes for the gender imbal-
ance. The literature has remained some-
what conflicting as to whether there is a
higher age-adjusted incidence of AD in
women with some studies finding no dif-
ference (3, 4) and others suggesting that
women have a higher incidence (5–8). Per-
haps, most striking is epidemiological evi-
dence from the Framingham study, which
reported that the age-specific lifetime risk
of AD is nearly twofold greater in women
than in men – 17.2 versus 9.1% at age
65 years and 28.5 versus 10.2% at age
75 years (6). This has sparked further atten-
tion into how gender may influence AD
pathophysiology (2).
Cognitive tests commonly used to
screen for AD or measure progression in
routine practice (e.g., MMSE) are also
known to show gender differences – sug-
gesting that factors such as detection
bias, cognitive reserve/education, or socio-
cultural effects could potentially also con-
tribute to gender differences in AD rates.
For example, a meta-analyses of cogni-
tive test scores in AD studies has found
that women perform significantly worse
than men (9). However, the emergence of
biomarker tests, such as CSF, brain vol-
umetric MRI, and amyloid and tau PET
scans, has allowed for a more unbiased
investigation of how gender affects pathol-
ogy and neuronal loss at both preclinical
and clinical stages of the disease. Selected
studies indicative of gender differences in
atrophy, pathology, longitudinal cognitive
changes, and diagnostic progression in AD
are summarized below.
Data from the Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) have been
used to examine gender differences in bio-
markers and cognition. Hua et al. exam-
ined 1-year atrophy rates, using 3D-tensor
based MRI morphometry in 1368 MRI
scans (144 subjects with AD, 338 subjects
with MCI, and 202 controls scanned twice)
and found that annual atrophy rates were
faster in women by 1–1.5% (10). Further,
atrophy rates correlated with amyloid-beta
and tau changes in CSF and with APOE4
allele status. Holland et al. (11) studied
668 subjects (normal, MCI, and AD) and
examined gender effects on brain atrophy
and cognitive decline (on ADAS-Cog and
CDS-SB) over a 3-year-period in a linear
mixed effects model controlling for age,
education, ApoE4, and baseline cognition.
In general, women showed greater atrophy
rates and faster cognitive decline than men
with the added contribution of female gen-
der being equal to the magnitude of the
ApoE4 effect.
In a longitudinal clinicopathologic
study of 141 individuals with AD, MCI,
or cognitive impairment, using clinical and
post-mortem data, a significant correlation
was found between gender and neuritic
plaques and neurofibrillary tangles after
controlling for age (12). In the same investi-
gation, each unit increase on a global mea-
sure of AD pathology was found to increase
odds of clinical AD by 20-fold for women as
opposed to 3-fold for men (12). With each
additional unit of global AD pathology, the
cognitive function scores in episodic mem-
ory, semantic memory, working memory,
perceptual speed, and visuospatial ability
were reduced significantly more in women
than in men (12), suggesting a greater cog-
nitive vulnerability to AD pathology in
women, or greater cognitive reserve in men.
In a separate study, steeper rates of cogni-
tive decline, decreasing brain volume, and
progression from MCI to AD, have been
found in women (13).
Studies have also examined whether
genetic and hormonal mechanisms con-
tribute to the sex disparities in Alzheimer’s
risk and pathology. Some have indicated
a greater potency of the risk associated
with APOE4 allele in women (14). Changes
in fMRI default mode connectivity and
increased CSF tau level in APOE4 carri-
ers have been linked to female gender (15).
Premature centromere separation (PCS),
a consequence of chromosome instability,
has been shown to be more common in
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both females with AD and normal females
than in men (16), and in AD, the X-PCS
phenotype is accelerated in women (17).
Carriers of X-linked mutations show pro-
gressive neurodegeneration and ataxia with
age (17); together with the finding of X-
PCS predominance in AD, this suggests
a susceptibility of the X-chromosome to
AD-driven changes. Significantly, the AD
brain demonstrates a twofold increase of
X-chromosome aneuploidy rates in neural
cells of the hippocampus and cerebrum,
which are the brain areas most affected by
neurodegeneration (18). At the epigenetic
level, X-inactivation patterns affecting both
coding and non-coding regions may cause
a female individual to face both a large gene
dosage and sex-specific effects (19), which
could disproportionately increase female
vulnerability to AD. Mean X-chromosome
expression has also shown to be associated
with neuronal density (20).
Estrogen has been shown to poten-
tially reduce amyloid-beta aggregation and
improve a variety of neural functions (hip-
pocampal dendritic spine health, cere-
bral blood flow and glucose metabolism,
increase choline acetyltransferase activity,
etc.) (13). Hence, the sharp decline in estro-
gen levels during menopause could be a sig-
nificant contributor. Four estrogen recep-
tor beta (ESR2) single-nucleotide poly-
morphisms (SNPs) were found to be asso-
ciated with increased risk of AD (21). Sex
hormones, including estrogen, may also be
involved in promoting non-amyloidogenic
pathways (alpha-secretase pathway) and
decreasing amyloid-beta production (22).
However, in the 5-year WHIMS study,
risk of MCI or AD diagnosis increased by
37% in an estrogen plus progestin treat-
ment cohort (23) and deleterious effects
on frontal lobe and hippocampal volumes
were observed in women assigned to hor-
mone therapy (24). Estrogen and testos-
terone replacement therapies have also not
benefited AD patients in multicenter con-
trolled trials. Reconciling these paradoxical
findings, given all the nuances of hormonal
therapy, should be priority for the field.
Our current understanding of AD is
that its pathogenesis may begin decades
before the manifestation of clinical demen-
tia – a stage now termed as preclinical
AD. Indeed, in people at risk for famil-
ial autosomal dominant AD (carriers of
PSEN and APP mutations), silent amyloid-
beta changes have been noted some 25 years
before predicted onset of clinical disease.
Available evidence does not pinpoint any
one biological basis for sex differences in
Alzheimer’s susceptibility but suggest that
gender affects multiple processes in AD
including the manifestation of genetic risk,
cognitive reserve, cognitive testing per-
formance, brain atrophy rates, and neu-
rotransmitter profiles. However, existing
biomarker studies on gender differences
in AD have been largely post hoc and
exploratory in nature. Further examina-
tion of gender effects in longitudinal mul-
ticenter studies, such as Alzheimer Dis-
ease Neuroimaging Initiative-2 (ADNI-
2), Dominant Inherited Alzheimer Net-
work (DIAN), Alzheimer’s Prevention Ini-
tiative (API), the Amyloid Lowering Trial
in Asymptomatic Individuals (A4 trial),
as well as ongoing large population stud-
ies (e.g., Baltimore Study of Aging, Fram-
ingham Study, Women’s Health Initiative,
Rotterdam Study of Aging) could be next
steps. If gender differences are confirmed,
then current models of the timeline of bio-
marker evolution in AD should be modi-
fied to incorporate timeline curves specific
for men versus women. Indeed, gender-
stratified clinical treatment trials may be
logical if gender-specific pathological dif-
ferences exist.
Over the next 50 years, barring a cure,
the share of the burden born by women
may rise much faster than it will for men.
It is time to set aside old stereotypes, and
prioritize gender-specific research in AD.
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